Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.36M Buy
56,357
+8,185
+17% +$214K 0.12% 153
2026
Q1
$1.35M Buy
48,172
+3,526
+8% +$93.9K 0.17% 132
2025
Q4
$1.11M Sell
44,646
-7,738
-15% -$195K 0.14% 149
2025
Q3
$1.33M Sell
52,384
-1,574
-3% -$38.8K 0.16% 148
2025
Q2
$1.31M Buy
53,958
+685
+1% +$16K 0.16% 144
2025
Q1
$1.34M Sell
53,273
-6,760
-11% -$177K 0.16% 152
2024
Q4
$1.59M Buy
60,033
+9,408
+19% +$255K 0.19% 135
2024
Q3
$1.47M Sell
50,625
-2,350
-4% -$68.6K 0.2% 136
2024
Q2
$1.48M Buy
52,975
+13,988
+36% +$385K 0.22% 128
2024
Q1
$1.08M Buy
38,987
+17,430
+81% +$484K 0.18% 150
2023
Q4
$621K Sell
21,557
-3,036
-12% -$91.8K 0.12% 167
2023
Q3
$816K Sell
24,593
-898
-4% -$31.8K 0.2% 126
2023
Q2
$935K Buy
25,491
+3,153
+14% +$123K 0.24% 110
2023
Q1
$911K Buy
22,338
+5,612
+34% +$242K 0.32% 92
2022
Q4
$748K Sell
16,726
-451
-3% -$21.6K 0.21% 113
2022
Q3
$752K Buy
17,177
+3,245
+23% +$158K 0.31% 76
2022
Q2
$730K Buy
+13,932
New +$710K 0.3% 80

Other funds holding PFE

Naviter Wealth's PFE Position: Q2 2026 in Review

Naviter Wealth increased its Pfizer (PFE) stake by 17% in Q2 2026, buying an estimated $214K and bringing the position to 56,357 shares worth $1.36M. The position accounts for 0.12% of the portfolio, ranked #153.

Naviter Wealth first reported a position in PFE in Q2 2022 and has held it in 17 quarters since. The position peaked at $1.59M in Q4 2024. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Naviter Wealth held 56,357 shares of Pfizer worth $1.36M as of Q2 2026.
  • Naviter Wealth bought 8,185 Pfizer shares in Q2 2026, an estimated $214K.
  • Pfizer made up 0.12% of Naviter Wealth's portfolio in Q2 2026, its #153 holding.
  • Naviter Wealth first reported a position in Pfizer in Q2 2022 and has held it in 17 quarters since.
  • Naviter Wealth's Pfizer position peaked at $1.59M in Q4 2024.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Naviter Wealth's 13F filing for Q2 2026, filed 7 Aug 2026.